REGENXBIO Reports Q3 2026 Financial Results Amid Patent Expirations and Litigation Settlement
REGENXBIO (RGNX) reported third-quarter 2026 revenues of $9.2 million, a significant decrease from $29.7 million in the prior year due to patent expirations affecting ZOLGENSMA royalty income. Despite the revenue decline, the company narrowed its net loss to $40.7 million ($0.62 per share) compared to a $61.9 million loss in Q3 2025. The results were bolstered by a $38 million gain from a patent litigation settlement with Sarepta Therapeutics and a $100 million milestone payment from AbbVie. The company maintains a strong liquidity position with $251 million in cash and equivalents, supplemented by an additional $39 million received from the Sarepta settlement. Management expects this cash runway to extend into late 2027, supporting clinical milestones for the RGX-202 program. While R&D expenses rose to $61 million due to ongoing clinical trials, the company continues to advance its gene therapy pipeline, including large-scale enrollment for Sura-vec.
Tickers: $ABBV $NVS $RGNX $SRPT
Topics: earnings report litigation settlement net loss patent expiration revenue decline
Read the full article at Motley Fool
Part of the story REGENXBIO Reports Q3 2026 Financial Results Amid Patent Expirations and Litigation Settlement (3 articles)